Composition for preventing or treating cancer, comprising ivermectin and anticancer agent
The combination of ivermectin with anticancer agents in specific ratios enhances cancer treatment efficacy by inhibiting cancer cell growth and inducing apoptosis, addressing the limitations of individual drugs and improving treatment outcomes for diverse cancer types.
Patent Information
- Application Number
- PCT/KR2024/095823
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-05-17
- Filing Date
- 2024-05-17
- Publication Date
- 2024-11-28
AI Technical Summary
Current cancer treatments face challenges due to cancer recurrence and resistance to anticancer drugs, primarily because of diverse cancer mutations and limited targeting capabilities, leading to severe side effects and ultimately, metastatic and recurrent cancer.
A composition combining ivermectin with anticancer agents such as irinotecan, cisplatin, gemcitabine, fluorouracil, paclitaxel, and doxorubicin, administered in specific concentration ratios, to enhance cancer cell inhibition and induce apoptosis, thereby overcoming individual drug limitations.
The combination significantly inhibits cancer cell growth and induces apoptosis, demonstrating a synergistic effect that increases the anticancer treatment efficacy compared to single-agent administration, effectively targeting various types of cancer cells.
Smart Images

Figure KR2024095823_28112024_PF_FP_ABST
Abstract
Description
Composition for preventing or treating cancer comprising ivermectin and an anticancer agent
[0001] The present invention relates to a composition for preventing or treating cancer, comprising ivermectin and an anticancer agent, and an anticancer adjuvant.
[0002]
[0003] While normal cells can grow and regenerate in a regular and elastic manner as needed, cancer cells proliferate without restraint. These cells form a mass of undifferentiated cells, also known as a tumor. These cancer cells invade surrounding tissues and metastasize to other organs, causing severe pain and ultimately death. Despite medical advancements, the number of cancer patients in Korea has steadily increased, rising by approximately 44% over the past decade. The international anticancer drug market has also grown, reaching an annual market size of approximately $100 billion.
[0004] Anticancer drugs include first-generation chemotherapy, second-generation targeted therapy, and third-generation immunotherapy, which are being developed to overcome the side effects of these drugs. Research continues on this topic. However, the biggest challenge in current cancer treatment is cancer recurrence. This is because cancer mutations are diverse, making it difficult to target specific cancers. Furthermore, resistance to the chemotherapy used in the treatment of relapsed cancers is common. Ultimately, even after treating the primary cancer, most patients die from metastasis or relapse. Therefore, combination therapy strategies are being proposed to enhance the efficacy of chemotherapy.
[0005] Meanwhile, ivermectin, used as an anthelmintic, has been reported to have an agonist function of FXR (farnesoid x receptor). FXR is a member of the nuclear hormone receptor superfamily and is mainly expressed in the liver, kidney, and intestine. Generally, FXR is known to be highly expressed in normal cells and its expression is downregulated in cancer or tumors. In addition, FXR activation has been confirmed to increase the expression of several pro-apoptotic genes, including FAS, BAK1, P21, KLF4, FADD, CAS9, and P27, and when activated in colon cancer cells, it induces apoptosis, resulting in the elimination of genetically modified tumor cells (Guofeng Xie and Jean-Pierre Raufman, J Cancer Metastasis Treat, 2:24-28, 2016).
[0006] In addition, ivermectin has been reported to have antitumor effects in many cancers, including breast cancer, ovarian cancer, prostate cancer, head and neck cancer, colon cancer, pancreatic cancer, and malignant melanoma, in in vitro experiments, and has been reported to exhibit an antiangiogenic effect as well as an inhibition of cancer cell proliferation and induction of cell death.
[0007]
[0008] Accordingly, the inventors of the present invention have made great efforts to provide a combination anticancer agent capable of significantly inhibiting cancer cells, and as a result, have confirmed that the cancer cell inhibition effect is significantly increased when ivermectin and an anticancer agent are used in combination compared to when each is used alone, and have completed the present invention.
[0009]
[0010] Accordingly, the purpose of the present invention is to provide a pharmaceutical composition for preventing or treating cancer comprising ivermectin and an anticancer agent as active ingredients.
[0011] Another object of the present invention is to provide an anticancer adjuvant comprising ivermectin and an anticancer agent as active ingredients.
[0012]
[0013] To achieve the above-mentioned purpose,
[0014] The present invention relates to ivermectin; and
[0015] A composition for preventing or treating cancer is provided, comprising at least one anticancer agent selected from the group consisting of irinotecan, cisplatin, gemcitabine, fluorouracil (5-FU), paclitaxel, doxorubicin, and pharmaceutically acceptable salts thereof.
[0016] In addition, the present invention relates to ivermectin; and
[0017] An anticancer adjuvant comprising at least one anticancer agent selected from the group consisting of irinotecan, cisplatin, gemcitabine, fluorouracil (5-FU), paclitaxel, doxorubicin, and pharmaceutically acceptable salts thereof is provided.
[0018] According to a preferred embodiment of the present invention, the cancer may be pancreatic cancer, liver cancer, lung cancer, stomach cancer, colon cancer, prostate cancer, kidney cancer, breast cancer, or ovarian cancer.
[0019] According to another preferred embodiment of the present invention, when the anticancer agent is irinotecan or a pharmaceutically acceptable salt thereof, the cancer is pancreatic cancer, lung cancer or stomach cancer.
[0020] If the above anticancer agent is cisplatin or a pharmaceutically acceptable salt thereof, the cancer is colon cancer or ovarian cancer,
[0021] If the above anticancer agent is gemcitabine or a pharmaceutically acceptable salt thereof, the cancer is breast cancer or ovarian cancer,
[0022] If the above anticancer agent is fluorouracil or a pharmaceutically acceptable salt thereof, the cancer is gastric cancer or breast cancer,
[0023] If the above anticancer agent is paclitaxel or a pharmaceutically acceptable salt thereof, the cancer is pancreatic cancer, stomach cancer, colon cancer, prostate cancer, kidney cancer, breast cancer or ovarian cancer,
[0024] When the anticancer agent is doxorubicin or a pharmaceutically acceptable salt thereof, the cancer may be pancreatic cancer, liver cancer, lung cancer, colon cancer, kidney cancer, breast cancer, or ovarian cancer.
[0025] According to another preferred embodiment of the present invention, the ivermectin and the anticancer agent may be included in a concentration ratio of 0.2:1 to 1500:1, and more preferably, the ivermectin and irinotecan are included in a concentration ratio of 0.2:1 to 2:1.
[0026] Ivermectin and cisplatin in a concentration ratio of 0.8:1 to 6:1,
[0027] Ivermectin and gemcitabine in a concentration ratio of 2:1 to 15:1,
[0028] Ivermectin and fluorouracil in a concentration ratio of 0.4:1 to 3:1,
[0029] Ivermectin and paclitaxel in a concentration ratio of 200:1 to 1500:1,
[0030] Ivermectin and doxorubicin may be included in a concentration ratio of 2:1 to 15:1.
[0031] According to another preferred embodiment of the present invention, the ivermectin and the anticancer agent may be administered sequentially or simultaneously.
[0032]
[0033] The present invention also relates to ivermectin; and
[0034] A method for preventing or treating cancer is provided, comprising administering to a subject in need thereof a composition comprising, as an active ingredient, at least one anticancer agent selected from the group consisting of irinotecan, cisplatin, gemcitabine, fluorouracil (5-FU), paclitaxel, doxorubicin, and pharmaceutically acceptable salts thereof.
[0035]
[0036] The composition comprising ivermectin and an anticancer agent of the present invention not only significantly reduced the growth of various cancer cells compared to when ivermectin or the anticancer agent is used alone, but also confirmed a synergistic anticancer effect when combined with the anticancer agents. Therefore, the composition of the present invention can be usefully utilized as an effective combination anticancer agent.
[0037]
[0038] Figure 1 shows data confirming the cancer cell growth rate when ivermectin and / or various anticancer drugs (irinotecan, cisplatin, gemcitabine, fluorouracil, paclitaxel, and doxorubicin) were treated alone or in combination in (A) MIA PaCa-2 cells and (B) Su.8686 cells, which are pancreatic cancer cell lines. In the figure, Iver. represents ivermectin, Irino. represents irinotecan, Cis. represents cisplatin, Gem. represents gemcitabine, 5-FU represents fluorouracil, Pacil. represents paclitaxel, and Doxo. represents doxorubicin.
[0039] Figure 2 shows data confirming the cancer cell growth rate when ivermectin and / or various anticancer drugs were treated alone or in combination to (A) Hep3B cells and (B) SK-Hep1 cells, which are liver cancer cell lines.
[0040] Figure 3 shows data confirming the cancer cell growth rate when ivermectin and / or various anticancer drugs were treated alone or in combination to (A) A549 cell line and (B) H460 cell line, which are lung cancer cell lines.
[0041] Figure 4 shows data confirming the cancer cell growth rate when ivermectin and / or various anticancer drugs were treated alone or in combination to (A) MKN28 cells and (B) AGS cells, which are gastric cancer cell lines.
[0042] Figure 5 shows data confirming the cancer cell growth rate when ivermectin and / or various anticancer drugs were treated alone or in combination to (A) HCT116 cells and (B) HT29 cells, which are colon cancer cell lines.
[0043] Figure 6 shows data confirming the cancer cell growth rate when ivermectin and / or various anticancer drugs were treated alone or in combination to (A) PC-3 cells and (B) Du-145 cells, which are prostate cancer cell lines.
[0044] Figure 7 shows data confirming the cancer cell growth rate when ivermectin and / or various anticancer drugs were treated alone or in combination to (A) ACHN cells and (B) CAKI-1 cells, which are renal cell lines.
[0045] Figure 8 shows data confirming the cancer cell growth rate when ivermectin and / or various anticancer drugs were treated alone or in combination to (A) MCF-7 cells and (B) MDA-MB-231 cells, which are breast cancer cell lines.
[0046] Figure 9 shows data confirming the cancer cell growth rate when ivermectin and / or various anticancer drugs were treated alone or in combination to (A) OVCAR-3 cells and (B) OVCAR-8 cells, which are ovarian cancer cell lines.
[0047]
[0048] Hereinafter, the present invention will be described in detail.
[0049]
[0050] The present invention relates to a method for treating a subject, comprising the steps of: providing a method for treating a subject, comprising: providing ...
[0051] The present invention relates to a composition for preventing or treating cancer, comprising at least one anticancer agent selected from the group consisting of irinotecan, cisplatin, gemcitabine, fluorouracil (5-FU), paclitaxel, doxorubicin, and pharmaceutically acceptable salts thereof.
[0052] The present invention, from another consistent point of view, comprises ivermectin; and
[0053] The present invention relates to an anticancer adjuvant comprising at least one anticancer agent selected from the group consisting of irinotecan, cisplatin, gemcitabine, fluorouracil (5-FU), paclitaxel, doxorubicin, and pharmaceutically acceptable salts thereof.
[0054] In the present invention, the cancer may be pancreatic cancer, liver cancer, lung cancer, stomach cancer, colon cancer, prostate cancer, kidney cancer, breast cancer, or ovarian cancer.
[0055] Specifically, when the anticancer agent is irinotecan or a pharmaceutically acceptable salt thereof, the cancer is pancreatic cancer, lung cancer or stomach cancer,
[0056] If the above anticancer agent is cisplatin or a pharmaceutically acceptable salt thereof, the cancer is colon cancer or ovarian cancer,
[0057] If the above anticancer agent is gemcitabine or a pharmaceutically acceptable salt thereof, the cancer is breast cancer or ovarian cancer,
[0058] If the above anticancer agent is fluorouracil or a pharmaceutically acceptable salt thereof, the cancer is gastric cancer or breast cancer,
[0059] If the above anticancer agent is paclitaxel or a pharmaceutically acceptable salt thereof, the cancer is pancreatic cancer, stomach cancer, colon cancer, prostate cancer, kidney cancer, breast cancer or ovarian cancer,
[0060] When the anticancer agent is doxorubicin or a pharmaceutically acceptable salt thereof, the cancer may be pancreatic cancer, liver cancer, lung cancer, colon cancer, kidney cancer, breast cancer, or ovarian cancer.
[0061] In the present invention, the ivermectin and the anticancer agent may be included in a concentration ratio of 0.2:1 to 1500:1.
[0062] More preferably, the ivermectin and irinotecan are used in a concentration ratio of 0.2:1 to 2:1.
[0063] Ivermectin and cisplatin in a concentration ratio of 0.8:1 to 6:1,
[0064] Ivermectin and gemcitabine in a concentration ratio of 2:1 to 15:1,
[0065] Ivermectin and fluorouracil in a concentration ratio of 0.4:1 to 3:1,
[0066] Ivermectin and paclitaxel in a concentration ratio of 200:1 to 1500:1,
[0067] Ivermectin and doxorubicin may be included in a concentration ratio of 2:1 to 15:1.
[0068]
[0069] More preferably, the ivermectin and irinotecan are used in a concentration ratio of 0.5:1 to 1.5:1.
[0070] Ivermectin and cisplatin in a concentration ratio of 1.5:1 to 4:1,
[0071] Ivermectin and gemcitabine in a concentration ratio of 4:1 to 10:1,
[0072] Ivermectin and fluorouracil in a concentration ratio of 0.8:1 to 2:1,
[0073] Ivermectin and paclitaxel in a concentration ratio of 400:1 to 1000:1,
[0074] Ivermectin and doxorubicin may be included in a concentration ratio of 4:1 to 10:1.
[0075]
[0076] In the present invention, the ivermectin and the anticancer agent may be administered sequentially or simultaneously.
[0077]
[0078] In a specific embodiment of the present invention, when ivermectin and an anticancer drug (irinotecan, cisplatin, gemcitabine, fluorouracil, paclitaxel, doxorubicin) were treated alone or in combination with cell lines derived from pancreatic cancer, liver cancer, lung cancer, stomach cancer, colon cancer, prostate cancer, kidney cancer, breast cancer, and ovarian cancer, an anticancer synergistic effect according to the combined administration of anticancer drugs was confirmed.
[0079]
[0080] Confirmation of synergistic effect by combined administration of anticancer drugs CancerCell Line Synergy effect Pancreatic cancer MIA PaCa-2 Irinotecan, paclitaxel, doxorubicin Su.86.86 Irinotecan, cisplatin, gemcitabine, paclitaxel, doxorubicin Liver cancer Hep3 B Irinotecan, 5-FU, paclitaxel, doxorubicin SK-Hep1 Cisplatin, doxorubicin Lung cancer A549 Irinotecan, cisplatin, doxorubicin H460 Irinotecan, paclitaxel, doxorubicin Stomach cancer MKN28 Irinotecan, 5-FU, paclitaxel, doxorubicin AGS Irinotecan, cisplatin, 5-FU, paclitaxel, doxorubicin Colon cancer Cancer)HCT116Cisplatin, paclitaxel, doxorubicinHT29Cisplatin, paclitaxel, doxorubicinProstate CancerPC-35-FU, paclitaxel, doxorubicinDu-145Irinotecan, cisplatin, gemcitabine, paclitaxel, doxorubicinKidney cancerACHNirinotecan, cisplatin, gemcitabine, paclitaxel, doxorubicinCAKI-1Paclitaxel, doxorubicinBreast CancerMCF-7Gemcitabine, 5-FU, paclitaxel, doxorubicinMDA-MB-231Irinotecan, cisplatin, gemcitabine, 5-FU, paclitaxel, doxorubicinOvarian CancerOVCAR-3Irinotecan, cisplatin, gemcitabine, 5-FU, paclitaxel, doxorubicin OVCAR-8 Cisplatin, gemcitabine, paclitaxel, doxorubicin
[0081] As a result, as shown in Table 1 and Figures 1 to 8, in the case of combined administration of ivermectin + irinotecan, in pancreatic cancer, lung cancer, and gastric cancer cell lines,
[0082] In the case of combined administration of ivermectin and cisplatin, in colon cancer and ovarian cancer cell lines,
[0083] In the case of combined administration of ivermectin and gemcitabine, in breast cancer and ovarian cancer cell lines,
[0084] In the case of combined administration of ivermectin and fluorouracil, in gastric cancer and breast cancer cell lines,
[0085] In the case of combined administration of ivermectin and paclitaxel, in pancreatic cancer, gastric cancer, colon cancer, prostate cancer, renal cancer, breast cancer and ovarian cancer cell lines,
[0086] In the case of combined administration of ivermectin and doxorubicin, it was confirmed that the cancer cell killing effect was significantly increased compared to monotherapy in pancreatic cancer, liver cancer, lung cancer, colon cancer, kidney cancer, breast cancer, and ovarian cancer cell lines.
[0087]
[0088] The composition of the present invention may be administered orally or parenterally in various dosage forms. When formulating the composition, it may be prepared using one or more buffers (e.g., saline or PBS), antioxidants, bacteriostatic agents, chelating agents (e.g., EDTA or glutathione), fillers, bulking agents, binders, adjuvants (e.g., aluminum hydroxide), suspending agents, thickening agents, wetting agents, disintegrating agents, or surfactants, diluents, or excipients.
[0089] Solid dosage forms for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid dosage forms are prepared by mixing one or more compounds with at least one excipient, such as starch (including corn starch, wheat starch, rice starch, potato starch, etc.), calcium carbonate, sucrose, lactose, dextrose, sorbitol, mannitol, xylitol, erythritol maltitol, cellulose, methyl cellulose, sodium carboxymethylcellulose, and hydroxypropylmethyl-cellulose or gelatin. For example, tablets or sugar-coated tablets can be obtained by mixing an active ingredient with a solid excipient, grinding the mixture, adding a suitable auxiliary agent, and then processing the mixture into a granule mixture.
[0090] In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral administration include suspensions, solutions, emulsions, and syrups, and in addition to commonly used simple diluents such as water and liquid paraffin, various excipients such as wetting agents, sweeteners, fragrances, or preservatives may be included. In addition, cross-linked polyvinylpyrrolidone, agar, alginic acid, or sodium alginate may be added as disintegrants in some cases, and anticoagulants, lubricants, wetting agents, fragrances, emulsifiers, and preservatives may be additionally included.
[0091] Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations, or suppositories. Non-aqueous solutions and suspensions can include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate. Suppository bases include witepsol, macrogol, Tween 61, cocoa butter, laurin, glycerol, and gelatin.
[0092] The composition of the present invention can be administered orally or parenterally, and when administered parenterally, it can be formulated in the form of an injection for external use on the skin; intraperitoneally, rectally, intravenously, intramuscularly, subcutaneously, intrauterinely, or intracerebrally, according to a method known in the art.
[0093] In the case of the above injection, it must be sterilized and protected from contamination by microorganisms such as bacteria and fungi. Examples of suitable carriers for the injection include, but are not limited to, solvents or dispersion media including water, ethanol, polyols (e.g., glycerol, propylene glycol, and liquid polyethylene glycol), mixtures thereof, and / or vegetable oils. More preferably, suitable carriers include Hanks' solution, Ringer's solution, phosphate buffered saline (PBS) containing triethanolamine, or isotonic solutions such as sterile water for injection, 10% ethanol, 40% propylene glycol, and 5% dextrose. In order to protect the injection from microbial contamination, various antibacterial and antifungal agents such as parabens, chlorobutanol, phenol, sorbic acid, and thimerosal may be additionally included. In addition, the injection may in most cases additionally include isotonic agents such as sugars or sodium chloride.
[0094] The composition of the present invention is administered in a pharmaceutically effective amount. A pharmaceutically effective amount refers to an amount sufficient to treat a disease with a reasonable benefit / risk ratio applicable to medical treatment. The effective dosage level can be determined based on the type and severity of the patient's disease, the activity and sensitivity of the drug to the drug, the time of administration, the route of administration and excretion rate, the duration of treatment, factors including concurrently used drugs, and other factors well known in the medical field. The composition of the present invention can be administered as an individual therapeutic agent or in combination with other therapeutic agents, and can be administered sequentially or simultaneously with conventional therapeutic agents, and can be administered singly or in multiple doses. That is, the total effective amount of the composition of the present invention can be administered to a patient as a single dose, or can be administered as multiple doses in a fractionated treatment protocol for long-term administration. It is important to consider all of the above factors and administer an amount that achieves the maximum effect with the minimum amount without causing side effects, and this can be easily determined by those skilled in the art.
[0095] The preferred dosage of the above composition varies depending on the patient's condition, body weight, degree of disease, drug form, route of administration, and period of administration, but can be appropriately selected by those skilled in the art. For example, it can be administered at 0.0001 to 2,000 mg / kg per day, more preferably 0.001 to 2,000 mg / kg. Administration can be done once a day or divided into several doses. However, the scope of the present invention is not limited by the above dosage.
[0096] The composition of the present invention can be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy, and biological response modifiers.
[0097]
[0098] The anticancer adjuvant of the present invention refers to any form that enhances the anticancer effect of an anticancer agent or suppresses or ameliorates the side effects of the agent. The anticancer adjuvant of the present invention can be administered in combination with various types of anticancer agents or anticancer adjuvants. When administered in combination, even at lower doses than conventional anticancer agents, the anticancer therapeutic effect can be equivalent, thereby enabling safer anticancer treatment.
[0099] The above-mentioned anticancer adjuvant may be administered via any conventional route as long as it can reach the target tissue. The anticancer adjuvant of the present invention may be administered intraperitoneally, intravenously, intramuscularly, subcutaneously, orally, intrapulmonary, or rectally, depending on the intended purpose, but is not limited thereto. Furthermore, the anticancer adjuvant may be administered via any device capable of transporting the active substance to target cells.
[0100] The anticancer adjuvant of the present invention can be preferably formulated as an anticancer adjuvant by additionally including one or more pharmaceutically acceptable carriers in addition to the active ingredient for administration. Carriers, excipients or diluents that can be included in the anticancer treatment adjuvant of the present invention include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate and mineral oil.
[0101] The anticancer adjuvant of the present invention may be a formulation for oral or parenteral administration, and the description of the formulation is replaced with the description of the formulation of the pharmaceutical composition.
[0102]
[0103] Hereinafter, the present invention will be described in more detail through examples. These examples are intended solely to illustrate the present invention, and it will be apparent to those skilled in the art that the scope of the present invention is not limited by these examples.
[0104]
[0105] Example 1: Confirmation of anticancer activity against pancreatic cancer through combination therapy
[0106] In the present invention, to determine the effect of combined treatment with ivermectin and anticancer drugs on cancer cell growth, the degree of cancer cell death was determined through the Sulforhodamine B colorimetric assay (SRB) assay, and the cancer cell growth rate was analyzed compared to the control group (100%). All experiments were performed three times, and the data are expressed as average ± standard deviation (SD).
[0107]
[0108] First, pancreatic cancer cell lines, MIA PaCa-2 cells and Su.8686 cells, were prepared, and cells (100 μl) were seeded in 96-well cell culture plates at plating densities ranging from 5,000 to 20,000 cells / well depending on the doubling time of each cell line. After cell seeding, the plates were incubated for 24 h before the addition of experimental drugs. Ivermectin (4 μM to 10 μM) and / or anticancer drugs (irinotecan 2.5 μM, cisplatin 1 μM, gemcitabine 2.5 μM, 5-FU 5 μM, paclitaxel 10 nM, doxorubicin 1 μM) were treated alone or in combination, and the negative control group was treated with DMSO. The ivermectin treatment concentration was determined by the IC for each cell line. 50 It was set based on the value.
[0109] Next, after culturing in a CO2 incubator for 48 hours, the assay was terminated by adding cold trichloroacetic acid (TCA). Cells were fixed in situ by gently adding 50 μl of cold 50% (w / v) TCA (final concentration: 10% TCA) and incubated at 4°C for 60 minutes. The supernatant was discarded, and the plates were washed five times with distilled water and then air-dried. A 0.4% (w / v) sulforhodamine B (SRB) solution (100 μl) in 1% acetic acid was added to each well, and the plates were left at room temperature for 10 minutes. After staining, the plates were washed five times with 1% acetic acid to remove unbound dye, and the plates were air-dried. The bound dye was then solubilized with 10 mM trizma base, and the absorbance was recorded at 515 nm using an automated plate reader. The cancer cell growth rate according to drug administration is shown in the figure.
[0110]
[0111] In addition, the Colby equation was used to confirm the synergistic effect of anticancer activity according to combination administration. When the anticancer activity of two compounds combined is greater than the simple sum (expected activity) of the anticancer activities of each compound, this is called a synergistic effect. The predicted synergistic effect according to combination administration of the present invention can be calculated as follows using the Colby equation of the following mathematical formula 1 (SR, Colby, Weeds, 1967, 15, 20-22).
[0112]
[0113] [Mathematical Formula 1]
[0114] E = α + β-(α × β÷ 100)
[0115]
[0116] α and β are the measured anticancer activity values when each compound is treated alone, and E is the predicted value, which is the predicted anticancer activity when α and β are mixed.
[0117] In the present invention, the actual value of anticancer activity according to combination administration was expressed as cancer cell growth inhibition rate (%), and this was substituted into the Colby equation to measure the predicted value (E) according to combination administration. If the actual value is greater than the predicted value, it can be determined that there is a synergistic effect. In the present invention, in order to further verify the synergistic effect of combination administration, the predicted value calculated by the Colby equation was compared with the actual value.
[0118]
[0119] Confirmation of growth inhibition rate and anticancer synergistic effect on pancreatic cancer cell line (MIA PaCa-2)Cancer cell growth inhibition rate (%)(Actual value)Predicted value (%)Monotherapy DMSO0.000Ivermectin (7 μM)32.031Irinotecan (7 μM)23.088Cisplatin (2.5 μM)-5.611Gemcitabine (1 μM)53.1475-FU (5 μM)7.311Paclitaxel (10 nM)24.823Doxorubicin (1 μM)95.210IvermectinCombined administration DMSO0.000Ivermectin (7 μM)32.031Irinotecan (7 μM)56.20847.72Cisplatin (2.5 μM)27.88328.22Gemcitabine (1 μM)67.80368.155-FU (5 μM)35.84037.00Paclitaxel (10 nM)54.16848.90Doxorubicin (1 μM)105.52496.74
[0120]
[0121] Confirmation of growth inhibition rate and anticancer synergistic effect on pancreatic cancer cell line (Su.8686) Cancer cell growth inhibition rate (%) (measured) Predicted (%) Single administration DMSO 0.000 Ivermectin (5 μM) 38.907 Irinotecan (7 μM) 30.153 Cisplatin (2.5 μM) -18.501 Gemcitabine (1 μM) 64.39 95-FU (5 μM) 51.298 Paclitaxel (10 nM) 8.791 Doxorubicin (1 μM) 75.464 Ivermectin Combination administration DMSO 0.000 Ivermectin (5 μM) 38.907 Irinotecan (7 μM) 66.56 957.33 Cisplatin (2.5 μM) 41.89 127.60 Gemcitabine (1 μM)79.71878.255-FU (5 μM)69.65770.25Paclitaxel (10 nM)53.94144.28Doxorubicin (1 μM)94.07985.01
[0122] As a result, as shown in Fig. 1, Table 2, and Table 3, the combined administration of ivermectin and irinotecan, paclitaxel, or doxorubicin showed an enhanced anticancer effect in MIA PaCa-2 cells, and the combined administration of ivermectin and irinotecan, cisplatin, paclitaxel, or doxorubicin showed an enhanced anticancer effect in Su.8686 cells. In addition, it was confirmed that the combined administration of ivermectin and irinotecan, paclitaxel, or doxorubicin commonly showed an enhanced anticancer effect in pancreatic cancer cell lines.
[0123] That is, ivermectin and irinotecan in a concentration ratio of 0.7:1 to 1:1 for pancreatic cancer.
[0124] Ivermectin and paclitaxel in a concentration ratio of 500:1 to 700:1,
[0125] Ivermectin and doxorubicin showed enhanced anticancer effects when administered at a concentration ratio of 5:1 to 7:1.
[0126]
[0127] Example 2: Confirmation of anticancer activity against liver cancer through combined administration
[0128] An experiment was performed using the same method as in Example 1 using Hep-3B cells and SK-Hep1 cells, which are liver cancer cell lines.
[0129]
[0130] Confirmation of growth inhibition rate and anticancer synergistic effect on liver cancer cell line (Hep3B)Cancer cell growth inhibition rate (%)(Actual value)Predicted value (%)Monotherapy DMSO0.000Ivermectin (5 μM)58.033Irinotecan (7 μM)9.781Cisplatin (2.5 μM)5.756Gemcitabine (1 μM)24.8595-FU (5 μM)22.175Paclitaxel (10 nM)6.179Doxorubicin (1 μM)55.932IvermectinCombined administration DMSO0.000Ivermectin (5 μM)58.033Irinotecan (7 μM)63.31262.14Cisplatin (2.5 μM)57.13360.45Gemcitabine (1 μM)67.23268.475-FU (5 μM)68.32667.34Paclitaxel (10 nM)63.20660.63Doxorubicin (1 μM)98.55481.51
[0131] Confirmation of growth inhibition rate and anticancer synergistic effect on liver cancer cell line (SK-Hep1)Cancer cell growth inhibition rate (%)(Actual value)Predicted value (%)Monotherapy DMSO0.000Ivermectin (6 μM)55.528Irinotecan (7 μM)50.718Cisplatin (2.5 μM)8.919Gemcitabine (1 μM)78.9575-FU (5 μM)64.212Paclitaxel (10 nM)70.650Doxorubicin (1 μM)97.481IvermectinCombined administration DMSO0.000Ivermectin (6 μM)55.528Irinotecan (7 μM)75.54478.08Cisplatin (2.5 μM)64.00859.49Gemcitabine (1 μM)87.69990.645-FU (5 μM)75.21884.08Paclitaxel (10 nM)84.13686.95Doxorubicin (1 μM)112.92298.88
[0132] As a result, as shown in Fig. 2, Table 4, and Table 5, the combined administration of ivermectin and irinotecan, 5-FU, paclitaxel, or doxorubicin showed an enhanced anticancer effect in Hep3B cells, and the combined administration of ivermectin and cisplatin or doxorubicin showed an enhanced anticancer effect in SK-Hep1 cells. In addition, it was confirmed that the combined administration of ivermectin and paclitaxel or doxorubicin commonly showed an enhanced anticancer effect in liver cancer cell lines.
[0133] That is, ivermectin and paclitaxel in a concentration ratio of 500:1 to 600:1 for liver cancer.
[0134] Ivermectin and doxorubicin showed enhanced anticancer effects when administered at a concentration ratio of 5:1 to 6:1.
[0135]
[0136] Example 3: Confirmation of anticancer activity against lung cancer through combined administration
[0137] An experiment was performed using lung cancer cells, A549 cells and H460 cells, using the same method as in Example 1.
[0138]
[0139] Confirmation of growth inhibition rate and anticancer synergistic effect on lung cancer cell line (A549)Cancer cell growth inhibition rate (%)(Actual value)Predicted value (%)Mono administrationDMSO0.000Ivermectin (6 μM)68.959Irinotecan (7 μM)14.692Cisplatin (2.5 μM)4.162Gemcitabine (1 μM)69.8115-FU (5 μM)63.082Paclitaxel (10 nM)62.820Doxorubicin (1 μM)86.283IvermectinCombined administrationDMSO0.000Ivermectin (6 μM)68.959Irinotecan (7 μM)80.14473.52Cisplatin (2.5 μM)73.39470.25Gemcitabine (1 μM)88.73090.635-FU (5 μM)81.78388.54Paclitaxel (10 nM)82.28588.46Doxorubicin (1 μM)147.35695.74
[0140] Confirmation of growth inhibition rate and anticancer synergistic effect on lung cancer cell line (H460)Cancer cell growth inhibition rate (%)(Actual value)Predicted value (%)Mono administrationDMSO0.000Ivermectin (6 μM)43.930Irinotecan (7 μM)62.824Cisplatin (2.5 μM)39.583Gemcitabine (1 μM)89.2545-FU (5 μM)75.200Paclitaxel (10 nM)58.415Doxorubicin (1 μM)101.241IvermectinCombined administrationDMSO0.000Ivermectin (6 μM)43.930Irinotecan (7 μM)81.61179.16Cisplatin (2.5 μM)58.35966.12Gemcitabine (1 μM)90.80993.975-FU (5 μM)80.90686.09Paclitaxel (10 nM)92.99176.68Doxorubicin (1 μM)145.147100.70
[0141] As a result, as shown in Fig. 3, Table 6, and Table 7, the combined administration of ivermectin and irinotecan, cisplatin, or doxorubicin showed an enhanced anticancer effect in A549 cells, and the combined administration of ivermectin and irinotecan, paclitaxel, or doxorubicin showed an enhanced anticancer effect in H460 cells. In addition, it was confirmed that the combined administration of ivermectin and irinotecan or doxorubicin commonly showed an enhanced anticancer effect in lung cancer cell lines.
[0142] That is, ivermectin and irinotecan in lung cancer at a concentration ratio of 0.8:1 to 0.9:1.
[0143] Ivermectin and doxorubicin showed enhanced anticancer effects when administered at a concentration ratio of 5.5:1 to 6.5:1.
[0144]
[0145] Example 4: Confirmation of anticancer activity against gastric cancer through combined administration
[0146] An experiment was performed using MKN28 cells and AGS cells, which are stomach cancer cell lines, using the same method as in Example 1.
[0147]
[0148] Confirmation of growth inhibition rate and anticancer synergistic effect on gastric cancer cell line (MKN28) Cancer cell growth inhibition rate (%) (measured) Predicted (%) Single administration DMSO 0.000 Ivermectin (6 μM) 62.726 Irinotecan (7 μM) 13.991 Cisplatin (2.5 μM) 3.424 Gemcitabine (1 μM) 39.94 35-FU (5 μM) 34.706 Paclitaxel (10 nM) 24.031 Doxorubicin (1 μM) 73.270 Ivermectin Combination administration DMSO 0.000 Ivermectin (6 μM) 62.726 Irinotecan (7 μM) 69.98 5 67.94 Cisplatin (2.5 μM) 57.88 4 64.00 Gemcitabine (1 μM)71.84477.615-FU (5 μM)77.40675.66Paclitaxel (10 nM)73.71971.68Doxorubicin (1 μM)109.82790.04
[0149] Confirmation of growth inhibition rate and anticancer synergistic effect on gastric cancer cell line (AGS)Cancer cell growth inhibition rate (%)(Actual value)Predicted value (%)Monotherapy DMSO0.000Ivermectin (10 μM)84.245Irinotecan (7 μM)16.366Cisplatin (2.5 μM)-21.680Gemcitabine (1 μM)52.5305-FU (5 μM)42.965Paclitaxel (10 nM)39.838Doxorubicin (1 μM)159.579IvermectinCombined administration DMSO0.000Ivermectin (10 μM)84.245Irinotecan (7 μM)93.35286.82Cisplatin (2.5 μM)83.31980.83Gemcitabine (1 μM)87.05492.525-FU (5 μM)101.19491.01Paclitaxel (10 nM)92.94490.52Doxorubicin (1 μM)156.191109.39
[0150] As a result, as shown in Fig. 4, Table 8, and Table 9, MKN28 cells showed an enhanced anticancer effect following combined administration of ivermectin and irinotecan, 5-FU, paclitaxel, or doxorubicin, and AGS cells showed an enhanced anticancer effect following combined administration of ivermectin and irinotecan, cisplatin, 5-FU, paclitaxel, or doxorubicin. In addition, it was confirmed that gastric cancer cell lines commonly showed an enhanced anticancer effect following combined administration of ivermectin and irinotecan, 5-FU, paclitaxel, or doxorubicin.
[0151] That is, ivermectin and irinotecan in a concentration ratio of 0.85:1 to 1.5:1 for gastric cancer.
[0152] Ivermectin and fluorouracil in a concentration ratio of 2.4:1 to 4:1,
[0153] Ivermectin and paclitaxel in a concentration ratio of 600:1 to 1000:1,
[0154] Ivermectin and doxorubicin showed enhanced anticancer effects when administered at a concentration ratio of 6:1 to 10:1.
[0155]
[0156]
[0157] Example 5: Confirmation of anticancer activity against colon cancer through combined administration
[0158] The experiment was performed using the same method as in Example 1 using HCT116 cells and HT29 cells, which are colon cancer cell lines.
[0159]
[0160] Confirmation of growth inhibition rate and anticancer synergistic effect on colon cancer cell line (HCT116)Cancer cell growth inhibition rate (%)(Actual value)Predicted value (%)Mono administrationDMSO0.000Ivermectin (8 μM)72.922Irinotecan (7 μM)45.286Cisplatin (2.5 μM)-9.504Gemcitabine (1 μM)81.8645-FU (5 μM)66.942Paclitaxel (10 nM)93.288Doxorubicin (1 μM)143.069IvermectinCombined administrationDMSO0.000Ivermectin (8 μM)72.922Irinotecan (7 μM)79.17685.18Cisplatin (2.5 μM)72.59370.35Gemcitabine (1 μM)88.83195.095-FU (5 μM)78.79291.05Paclitaxel (10 nM)107.96098.18Doxorubicin (1 μM)159.246111.66
[0161] Confirmation of growth inhibition rate and anticancer synergistic effect on colon cancer cell line (HT29) Cancer cell growth inhibition rate (%) (Actual value) Predicted value (%) Single administration DMSO 0.000 Ivermectin (8 μM) 62.447 Irinotecan (7 μM) 29.621 Cisplatin (2.5 μM) -15.964 Gemcitabine (1 μM) 69.1225 -FU (5 μM) 61.990 Paclitaxel (10 nM) 94.935 Doxorubicin (1 μM) 82.748 Ivermectin Combination administration DMSO 0.000 Ivermectin (8 μM) 62.447 Irinotecan (7 μM) 73.140 73.57 Cisplatin (2.5 μM) 62.76 156.45 Gemcitabine (1 μM)80.37488.405-FU (5 μM)71.72285.73Paclitaxel (10 nM)103.80598.10Doxorubicin (1 μM)96.57993.52
[0162] As a result, as shown in Fig. 5, Table 10, and Table 11, it was confirmed that both HCT116 cells and HT29 cells showed enhanced anticancer effects following combined administration of ivermectin and cisplatin, paclitaxel, or doxorubicin.
[0163] That is, ivermectin and cisplatin in a concentration ratio of 3:1 to 3.5:1 for colon cancer.
[0164] Ivermectin and paclitaxel in a concentration ratio of 750:1 to 850:1,
[0165] Ivermectin and doxorubicin showed enhanced anticancer effects when administered at a concentration ratio of 7.5:1 to 8.5:1.
[0166]
[0167] Example 6: Confirmation of anticancer activity against prostate cancer according to combination administration
[0168] An experiment was performed using PC-3 cells and DU-145 cells, which are prostate cancer cells, using the same method as in Example 1.
[0169]
[0170] Prostate cancer cell line (PC-3) growth inhibition rate and anticancer synergistic effect confirmed Cancer cell growth inhibition rate (%) (actual value) Predicted value (%) Single administration DMSO 0.000 Ivermectin (6 μM) 72.65 1 Irinotecan (7 μM) 37.80 3 Cisplatin (2.5 μM) -0.75 3 Gemcitabine (1 μM) 56.97 75-FU (5 μM) 31.43 1 Paclitaxel (10 nM) 80.170 Doxorubicin (1 μM) 87.27 2 Ivermectin Combination administration DMSO 0.000 Ivermectin (6 μM) 72.65 1 Irinotecan (7 μM) 81.73 4 82.99 Cisplatin (2.5 μM) 68.64 3 72.45 Gemcitabine (1 μM)84.72388.235-FU (5 μM)81.50381.25Paclitaxel (10 nM)100.07594.58Doxorubicin (1 μM)122.74196.52
[0171] Prostate cancer cell line (DU-145) growth inhibition rate and anticancer synergistic effect confirmed Cancer cell growth inhibition rate (%) (measured) Predicted (%) Single administration DMSO 0.000 Ivermectin (8 μM) 52.25 4 Irinotecan (7 μM) 85.169 Cisplatin (2.5 μM) -6.18 2 Gemcitabine (1 μM) 119.7 165-FU (5 μM) 38.52 1 Paclitaxel (10 nM) 91.98 7 Doxorubicin (1 μM) 110.4 11 Ivermectin combination administration DMSO 0.000 Ivermectin (8 μM) 52.25 4 Irinotecan (7 μM) 100.97 392.92 Cisplatin (2.5 μM) 54.9 19 49.30 Gemcitabine (1 μM)125.729109.415-FU (5 μM)60.27270.65Paclitaxel (10 nM)120.20396.17Doxorubicin (1 μM)141.331104.97
[0172] As a result, as shown in Fig. 6, Table 12, and Table 13, combined administration of ivermectin with 5-FU, paclitaxel, or doxorubicin showed an enhanced anticancer effect in PC-3 cells, and combined administration of ivermectin with irinotecan, cisplatin, gemcitabine, paclitaxel, or doxorubicin showed an enhanced anticancer effect in Du-145 cells. In addition, combined administration of ivermectin with paclitaxel or doxorubicin commonly showed an enhanced anticancer effect in prostate cancer cell lines.
[0173] That is, ivermectin and paclitaxel in a concentration ratio of 600:1 to 800:1 for prostate cancer.
[0174] Ivermectin and doxorubicin showed enhanced anticancer effects when administered at a concentration ratio of 6:1 to 8:1.
[0175]
[0176] Example 7: Confirmation of anticancer activity against renal cell carcinoma through combination therapy
[0177] An experiment was performed using ACHN cells and CAKI-1 cells, which are kidney cancer cell lines, using the same method as in Example 1.
[0178]
[0179] Confirmation of growth inhibition rate and anticancer synergistic effect on renal cell carcinoma (ACHN) cell lineCancer cell growth inhibition rate (%)(Actual value)Predicted value (%)MonotherapyDMSO0.000Ivermectin (8 μM)79.037Irinotecan (7 μM)75.159Cisplatin (2.5 μM)2.178Gemcitabine (1 μM)108.2575-FU (5 μM)42.504Paclitaxel (10 nM)50.118Doxorubicin (1 μM)122.859Ivermectin combination therapyDMSO0.000Ivermectin (8 μM)79.037Irinotecan (7 μM)95.87294.79Cisplatin (2.5 μM)81.05879.49Gemcitabine (1 μM)110.133101.735-FU (5 μM)86.93087.95Paclitaxel (10 nM)91.30189.54Doxorubicin (1 μM)149.062104.79
[0180] Confirmation of growth inhibition rate and anticancer synergistic effect on renal cell carcinoma cell line (CAKI-1) Cancer cell growth inhibition rate (%) (measured) Predicted (%) Single administration DMSO 0.000 Ivermectin (10 μM) 72.130 Irinotecan (7 μM) 44.977 Cisplatin (2.5 μM) 11.238 Gemcitabine (1 μM) 105.18 95-FU (5 μM) 53.883 Paclitaxel (10 nM) 27.90 2 Doxorubicin (1 μM) 98.899 Ivermectin combination administration DMSO 0.000 Ivermectin (10 μM) 72.130 Irinotecan (7 μM) 83.718 84.66 Cisplatin (2.5 μM) 71.93 6 75.26 Gemcitabine (1 μM)99.016101.455-FU (5 μM)77.80987.15Paclitaxel (10 nM)84.55279.91Doxorubicin (1 μM)124.40899.69
[0181] As a result, as shown in Fig. 7, Tables 14 and 15, combined administration of ivermectin with irinotecan, cisplatin, gemcitabine, paclitaxel or doxorubicin showed an enhanced anticancer effect in ACHN cells, and combined administration of ivermectin with paclitaxel or doxorubicin showed an enhanced anticancer effect in CAKI-1 cells. In addition, combined administration of ivermectin with paclitaxel or doxorubicin commonly showed an enhanced anticancer effect in renal cell carcinoma cell lines.
[0182] That is, ivermectin and paclitaxel in a concentration ratio of 800:1 to 1000:1 for renal cancer.
[0183] Ivermectin and doxorubicin showed enhanced anticancer effects when treated at a concentration ratio of 8:1 to 10:1.
[0184]
[0185] Example 8: Confirmation of anticancer activity against breast cancer through combined administration
[0186] The experiment was performed using breast cancer cell lines MCF-7 cells and MDA-MB-231 cells using the same method as in Example 1.
[0187]
[0188] Confirmation of growth inhibition rate and anticancer synergistic effect on breast cancer cell line (MCF-7) Cancer cell growth inhibition rate (%) (measured) Predicted (%) Single administration DMSO 0.000 Ivermectin (4 μM) 62.209 Irinotecan (7 μM) 19.330 Cisplatin (2.5 μM) -6.278 Gemcitabine (1 μM) 53.66 55-FU (5 μM) 48.006 Paclitaxel (10 nM) 79.847 Doxorubicin (1 μM) 107.266 Ivermectin Combination administration DMSO 0.000 Ivermectin (4 μM) 62.209 Irinotecan (7 μM) 67.73 169.51 Cisplatin (2.5 μM) 57.58 159.84 Gemcitabine (1 μM)89.39082.495-FU (5 μM)83.31680.35Paclitaxel (10 nM)98.93692.38Doxorubicin (1 μM)117.788102.75
[0189] Confirmation of growth inhibition rate and anticancer synergistic effect on breast cancer cell line (MDA-MB-231) Cancer cell growth inhibition rate (%) (Actual value) Predicted value (%) Single administration DMSO 0.000 Ivermectin (8 μM) 73.160 Irinotecan (7 μM) 8.009 Cisplatin (2.5 μM) -5.194 Gemcitabine (1 μM) 38.28 15-FU (5 μM) 5.90 7 Paclitaxel (10 nM) 45.39 1 Doxorubicin (1 μM) 92.874 Ivermectin Combination administration DMSO 0.000 Ivermectin (8 μM) 73.160 Irinotecan (7 μM) 91.236 75.31 Cisplatin (2.5 μM) 82.612 71.77 Gemcitabine (1 μM)96.53883.435-FU (5 μM)87.29874.75Paclitaxel (10 nM)107.47785.34Doxorubicin (1 μM)124.38598.09
[0190] As a result, as shown in Fig. 8, Table 16 and Table 17, the combined administration of ivermectin and gemcitabine, 5-FU, paclitaxel or doxorubicin showed an enhanced anticancer effect in MCF-7 cells, and the combined administration of ivermectin and irinotecan, cisplatin, gemcitabine, 5-FU, paclitaxel or doxorubicin showed an enhanced anticancer effect in MDA-MB-23 cells. In addition, the combined administration of ivermectin and gemcitabine, 5-FU, paclitaxel or doxorubicin commonly showed an enhanced anticancer effect in breast cancer cell lines.
[0191] That is, ivermectin and gemcitabine in a concentration ratio of 4:1 to 8:1 for breast cancer.
[0192] Ivermectin and fluorouracil in a concentration ratio of 0.8:1 to 1.6:1,
[0193] Ivermectin and paclitaxel in a concentration ratio of 400:1 to 800:1,
[0194] Ivermectin and doxorubicin showed enhanced anticancer effects when administered at a concentration ratio of 4:1 to 8:1.
[0195]
[0196] Example 9: Confirmation of anticancer activity against ovarian cancer through combined administration
[0197] An experiment was performed using ovarian cancer cells, OVCAR-3 cells and OVCAR-8 cells, using the same method as in Example 1.
[0198]
[0199] Confirmation of growth inhibition rate and anticancer synergistic effect on ovarian cancer cell line (OVCAR-3) Cancer cell growth inhibition rate (%) (measured) Predicted (%) Single administration DMSO 0.000 Ivermectin (8 μM) 72.233 Irinotecan (7 μM) 10.162 Cisplatin (2.5 μM) -7.868 Gemcitabine (1 μM) 36.34 35-FU (5 μM) 47.90 2 Paclitaxel (10 nM) 120.716 Doxorubicin (1 μM) 71.317 Ivermectin Combination administration DMSO 0.000 Ivermectin (8 μM) 72.233 Irinotecan (7 μM) 81.105 75.05 Cisplatin (2.5 μM) 74.27 270.05 Gemcitabine (1 μM)93.70182.325-FU (5 μM)96.58285.53Paclitaxel (10 nM)131.326105.75Doxorubicin (1 μM)118.30892.04
[0200] Confirmation of growth inhibition rate and anticancer synergistic effect on ovarian cancer cell line (OVCAR-8) Cancer cell growth inhibition rate (%) (Actual value) Predicted value (%) Single administration DMSO 0.000 Ivermectin (8 μM) 64.945 Irinotecan (7 μM) 38.954 Cisplatin (2.5 μM) -1.007 Gemcitabine (1 μM) 113.68 25-FU (5 μM) 48.733 Paclitaxel (10 nM) 96.840 Doxorubicin (1 μM) 92.138 Ivermectin Combination administration DMSO 0.000 Ivermectin (8 μM) 64.945 Irinotecan (7 μM) 77.68 0 78.60 Cisplatin (2.5 μM) 64.97 764.59 Gemcitabine (1 μM)123.321104.805-FU (5 μM)70.95582.03Paclitaxel (10 nM)136.69298.89Doxorubicin (1 μM)125.99597.24
[0201] As a result, as shown in Fig. 9, Tables 18 and 19, combined administration of ivermectin with irinotecan, cisplatin, gemcitabine, 5-FU, paclitaxel or doxorubicin showed an enhanced anticancer effect in OVCAR-3 cells, and combined administration of ivermectin with cisplatin, gemcitabine, paclitaxel or doxorubicin showed an enhanced anticancer effect in OVCAR-8 cells. In addition, combined administration of ivermectin with cisplatin, gemcitabine, paclitaxel or doxorubicin commonly showed an enhanced anticancer effect in ovarian cancer cell lines.
[0202] That is, ivermectin and cisplatin in a concentration ratio of 1.1:1 to 1.2:1 for ovarian cancer.
[0203] Ivermectin and gemcitabine in a concentration ratio of 3:1 to 3.5:1,
[0204] Ivermectin and paclitaxel in a concentration ratio of 750:1 to 850:1,
[0205] Ivermectin and doxorubicin showed enhanced anticancer effects when administered at a concentration ratio of 7.5:1 to 8.5:1.
[0206]
[0207] The composition comprising ivermectin and an anticancer agent of the present invention not only significantly reduced the growth of various cancer cells compared to when ivermectin or an anticancer agent is used alone, but also confirmed an anticancer synergistic effect according to combined administration of anticancer agents, and thus can be usefully utilized as an effective combination anticancer agent.
Claims
1. Ivermectin; and A composition for preventing or treating cancer, comprising at least one anticancer agent selected from the group consisting of irinotecan, cisplatin, gemcitabine, fluorouracil (5-FU), paclitaxel, doxorubicin, and pharmaceutically acceptable salts thereof.
2. In paragraph 1, A composition for preventing or treating cancer, characterized in that the cancer is pancreatic cancer, liver cancer, lung cancer, stomach cancer, colon cancer, prostate cancer, kidney cancer, breast cancer or ovarian cancer.
3. In paragraph 1, If the above anticancer agent is irinotecan or a pharmaceutically acceptable salt thereof, the cancer is pancreatic cancer, lung cancer or stomach cancer, If the above anticancer agent is cisplatin or a pharmaceutically acceptable salt thereof, the cancer is colon cancer or ovarian cancer, If the above anticancer agent is gemcitabine or a pharmaceutically acceptable salt thereof, the cancer is breast cancer or ovarian cancer, If the above anticancer agent is fluorouracil or a pharmaceutically acceptable salt thereof, the cancer is gastric cancer or breast cancer, If the above anticancer agent is paclitaxel or a pharmaceutically acceptable salt thereof, the cancer is pancreatic cancer, stomach cancer, colon cancer, prostate cancer, kidney cancer, breast cancer or ovarian cancer, A composition for preventing or treating cancer, characterized in that the cancer is pancreatic cancer, liver cancer, lung cancer, colon cancer, kidney cancer, breast cancer or ovarian cancer, when the anticancer agent is doxorubicin or a pharmaceutically acceptable salt thereof.
4. In paragraph 1, A composition for preventing or treating cancer, characterized in that the above ivermectin and anticancer agent are included in a concentration ratio of 0.2:1 to 1500:
1.
5. In paragraph 1, The above ivermectin and irinotecan are in a concentration ratio of 0.2:1 to 2:1, Ivermectin and cisplatin in a concentration ratio of 0.8:1 to 6:1, Ivermectin and gemcitabine in a concentration ratio of 2:1 to 15:1, Ivermectin and fluorouracil in a concentration ratio of 0.4:1 to 3:1, Ivermectin and paclitaxel in a concentration ratio of 200:1 to 1500:1, A composition for preventing or treating cancer, characterized in that ivermectin and doxorubicin are included in a concentration ratio of 2:1 to 15:
1.
6. In paragraph 1, A composition for preventing or treating cancer, characterized in that the ivermectin and the anticancer agent are administered sequentially or simultaneously.
7. Ivermectin; and An anticancer adjuvant comprising at least one anticancer agent selected from the group consisting of irinotecan, cisplatin, gemcitabine, fluorouracil (5-FU), paclitaxel, doxorubicin, and pharmaceutically acceptable salts thereof.
8. In paragraph 7, An anticancer adjuvant, characterized in that the cancer is pancreatic cancer, liver cancer, lung cancer, stomach cancer, colon cancer, prostate cancer, kidney cancer, breast cancer or ovarian cancer.
9. In paragraph 7, If the above anticancer agent is irinotecan or a pharmaceutically acceptable salt thereof, the cancer is pancreatic cancer, lung cancer or stomach cancer, If the above anticancer agent is cisplatin or a pharmaceutically acceptable salt thereof, the cancer is colon cancer or ovarian cancer, If the above anticancer agent is gemcitabine or a pharmaceutically acceptable salt thereof, the cancer is breast cancer or ovarian cancer, If the above anticancer agent is fluorouracil or a pharmaceutically acceptable salt thereof, the cancer is gastric cancer or breast cancer, If the above anticancer agent is paclitaxel or a pharmaceutically acceptable salt thereof, the cancer is pancreatic cancer, stomach cancer, colon cancer, prostate cancer, kidney cancer, breast cancer or ovarian cancer, An anticancer adjuvant, characterized in that the cancer is pancreatic cancer, liver cancer, lung cancer, colon cancer, kidney cancer, breast cancer or ovarian cancer, when the anticancer agent is doxorubicin or a pharmaceutically acceptable salt thereof.
10. In paragraph 7, An anticancer adjuvant, characterized in that the above ivermectin and anticancer agent are included in a concentration ratio of 0.2:1 to 1500:
1.
11. In paragraph 7, The above ivermectin and irinotecan are in a concentration ratio of 0.2:1 to 2:1, Ivermectin and cisplatin in a concentration ratio of 0.8:1 to 6:1, Ivermectin and gemcitabine in a concentration ratio of 2:1 to 15:1, Ivermectin and fluorouracil in a concentration ratio of 0.4:1 to 3:1, Ivermectin and paclitaxel in a concentration ratio of 200:1 to 1500:1, An anticancer adjuvant, characterized in that ivermectin and doxorubicin are included in a concentration ratio of 2:1 to 15:
1.
12. In paragraph 7, An anticancer adjuvant, characterized in that the above ivermectin and the anticancer agent are administered sequentially or simultaneously.
Citation Information
Patent Citations
Pharmaceutical combinations for the treatment of cancer
KR1020160106042A
Austenite stainless steel and manufacturing method
KR1020230166672A
